Loading...
•
Sep 30, 2023
Viridian Therapeutics Q3 2023 Earnings Report
Reported third quarter financial results and provided a corporate update.
Key Takeaways
Viridian Therapeutics reported its Q3 2023 financial results, highlighting the continuation of enrollment in the THRIVE and THRIVE-2 clinical trials for thyroid eye disease (TED) patients, the expected selection of a lead subcutaneous TED program by the end of 2023, and the advancement of a novel preclinical portfolio of FcRn inhibitors. The company also announced the appointment of Stephen Mahoney as President and CEO and closed a private placement of approximately $185 million to fund pipeline development and extend operating cash runway into 2026.
THRIVE and THRIVE-2 clinical trials are continuing to enroll active and chronic thyroid eye disease (TED) patients; expected delivery of topline clinical results for both clinical trials on track for 2024.
Timing for the selection of lead subcutaneous TED program is on track for the end of 2023.
Advancing recently announced novel preclinical portfolio of potentially best-in-class neonatal Fc receptor (FcRn) inhibitors with the broad potential to treat autoimmune diseases.
Closed a private placement of approximately $185 million with new and existing investors to fund pipeline development and extend operating cash runway into 2026.
Viridian Therapeutics
Viridian Therapeutics
Forward Guidance
Viridian Therapeutics is focused on advancing its anti-IGF-1R therapies and novel anti-FcRn portfolio, with key milestones expected in the near term.
Positive Outlook
- Topline clinical results for THRIVE and THRIVE-2 trials expected in 2024.
- Lead subcutaneous TED program selection on track for the end of 2023.
- IND submission for novel anti-FcRn portfolio planned by year end 2024.
- Private placement of approximately $185 million extends operating cash runway into 2026.
- Advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED).
Challenges Ahead
- Uncertainty and potential delays related to clinical drug development.
- The duration and impact of regulatory delays in our clinical programs.
- Manufacturing risks.
- Competition from other therapies or products.
- Estimates of market size.